This fixed combination consists of an anti-inflammatory inhalative corticosteroid and a long-acting bronchodilatory beta-2-sympathomimetic drug. The product is available as pMDI and DPI, too. Due to the synergism of both agents and its fast onset of action, it is indicated in the treatment of asthma bronchiale and COPD. Based on the Modulite® technology and the composition of DPI device, both products release extra fine formulations. This ensures high particle distribution mainly in the peripheral airways and allows reduction of the corticosteroid dosage.